



## Molecular Research in Neuropharmacology

Guest Editor:

### Dr. Ilaria Dettori

Department of Neuroscience,  
Psychology, Drug Research and  
Child Health (NEUROFARBA),  
University of Florence, 50139  
Florence, Italy

Deadline for manuscript  
submissions:

**31 July 2024**

### Message from the Guest Editor

Dear Colleagues,

Neurodegenerative disorders are devastating conditions, and the molecular and cellular mechanisms involved are still unclear. Moreover, the fact that the aging population is increasing as well as the incidence of these neurodegenerative conditions, such as Cerebral Ischemia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, creates an urgent need for new pharmacological targets.

In this Special Issue of *Biomedicines*, we invite your contributions, in the form of original research articles or reviews, on all aspects related to recent advances in the fields of pharmacology in brain diseases. Overall, I hope that this timely, focused Special Issue summarizing the current knowledge on innovative pharmacological therapeutic targets for neurological diseases will be of interest to a wide range of readers of the journal.

Dr. Ilaria Dettori

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)